Consensus Exelixis, Inc.

Stocks

EXEL

US30161Q1040

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 12/09/2026 am IST			5-day change	1st Jan Change
56.12 ^USD	-2.28%		-4.90%	+28.04%

11/09	Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid Inflation Data Release	MT
11/09	Exelixis, Inc. Extends FDA Review Period for Zanzalintinib New Drug Application in Combination with Atezolizumab for Metastatic Colorectal Cancer	CI

Evolution of the Average Target: Exelixis, Inc.

Evolution of the Target Price: Exelixis, Inc.

Changes in Analyst Recommendations: Exelixis, Inc.

11c16e47.56PcDcImJrP9G8jAywAEa9TAw5kWv00KZeKyyEnVtS0.osuydYMSQ-WHV5GOkTV-A533uq1C1xp_L4j2rBaH1x2Rzog0lnYU9JVBqw~108bfe8f1ebf8e36677173fda64fea16

Analysts' recommendations: Exelixis, Inc.

23/07	Analyst recommendations: Duke Energy, JPMorgan Chase, M&T Bank, Super Micro, Texas Instruments…
13/07	Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth…
07/07	RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating	MT
02/07	Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says	MT
02/07	UBS Adjusts Price Target on Exelixis to $52 From $43, Maintains Neutral Rating	MT
02/07	Analyst recommendations: Adobe, AA, Nike, Exelixis…
06/05	Exelixis Seen Trading Steady on Modest Drug Growth, RBC Says	MT
02/03	RBC Lowers Price Target on Exelixis to $43 From $46, Keeps Sector Perform Rating	MT
11/02	RBC Raises Price Target on Exelixis to $46 From $45, Keeps Sector Perform Rating	MT
02/02	Morgan Stanley Lifts Price Target on Exelixis to $49 From $48, Keeps Overweight Rating	MT
14/01	Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating	MT
09/01	Exelixis Shares Fall After Downgrade From Morgan Stanley	MT
08/01	Morgan Stanley Downgrades Exelixis to Equalweight, Price Target is $48	MT
05/01	Exelixis Faces Limited High-Impact Catalysts, BofA Says	MT
05/01	BofA Securities Downgrades Exelixis to Underperform From Neutral, Adjusts Price Target to $41 From $43	MT
06/11	UBS Adjusts Price Target on Exelixis to $40 From $35, Maintains Neutral Rating	MT
05/11	Morgan Stanley Lifts Price Target on Exelixis to $45 From $44, Keeps Overweight Rating	MT
04/11	Exelixis Shares Fall After Guggenheim Downgrade	MT
03/11	Guggenheim Downgrades Exelixis to Neutral From Buy	MT
22/25/22	Exelixis Shares Rise After Leerink Partners Upgrade	MT
21/25/21	Leerink Partners Upgrades Exelixis to Outperform From Market Perform, Adjusts Price Target to $48 From $38	MT
18/25/18	Exelixis, Inc. Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating Cabozantinib in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025	CI
30/25/30	UBS Adjusts Price Target on Exelixis to $38 From $43, Maintains Neutral Rating	MT
29/25/29	Analyst recommendations: Blackstone, Airbnb, Amphenol, Cadence Design Systems, Ameriprise Financial...
29/25/29	RBC Lowers Price Target on Exelixis to $45 From $50, Keeps Sector Perform Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	EXELIXIS, INC.					-4.33%
	WUXI APPTEC CO., LTD.					+23.69%
	ARGENX SE					+18.14%
	INSMED INCORPORATED					+54.69%
	WUXI BIOLOGICS (CAYMAN) INC.					+23.66%
	BIONTECH SE					+23.2%
	GENMAB A/S					+17.29%
	PHARMAESSENTIA CORPORATION					+9.16%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+32.94%
	SUMMIT THERAPEUTICS INC.					+66.45%
	Average					+26.49%
	Weighted average by Cap.					+25.42%